Reducing Selling, General and Administrative Expenses
First written in FY2018-Q1. 10 of 29 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026.
24 other companies' latest entry also says "Other".
- FY2026Higher R&D expenses due to upfront license fees and other costsAnnual report
「Although we worked to reduce costs, selling, general and administrative expenses increased by ¥1,087 million from the previous fiscal year due to higher R&D expenses, including upfront fees and other costs related to KRP-A225, a new drug candidate for SLE and other indications in-licensed in September 2025, and KRP-126 (BDT272), a treatment for neuropathic pain in-licensed in March 2026 (R&D expenses increased by ¥1,545 million).」
Although cost reductions were pursued, selling, general and administrative expenses, including R&D expenses, increased due to upfront fees and other costs related to the in-licensing of KRP-A225 and KRP-126. - 2026-05-12OtherInvestor presentation
「Selling, general and administrative expenses increased by ¥1,087 million from the previous fiscal year, despite efforts to reduce costs, due in part to the recording of upfront payments for in-licensed products; R&D expenses increased by ¥1,545 million.」
Although cost-reduction efforts were noted, total SG&A expenses increased due mainly to upfront payments for in-licensed products. - FY2026-H1Increase in R&D expenses associated with the acquisition of in-licensed productsAnnual report
「Selling, general and administrative expenses increased by ¥1,517 million from the same period of the previous year, mainly due to higher R&D expenses associated with the acquisition of in-licensed products and other factors (R&D expenses increased by ¥1,599 million).」
Despite the previous trend of cost reductions, selling, general and administrative expenses exceeded the prior-year level due to higher R&D expenses associated with the acquisition of in-licensed products and other factors. - FY2025-H1MitigatedAnnual report
「Selling, general and administrative expenses decreased by ¥485 million from the previous interim consolidated accounting period (R&D expenses increased by ¥1 million),」
Selling, general and administrative expenses decreased by ¥485 million year on year, while R&D expenses increased by ¥1 million. - FY2024Increase in selling, general and administrative expenses, decrease in R&D expensesAnnual report
「Selling, general and administrative expenses increased by ¥350 million from the previous fiscal year (R&D expenses decreased by ¥2,884 million).」
For the full fiscal year, selling, general and administrative expenses increased by ¥350 million year on year, while R&D expenses decreased by ¥2,884 million. - FY2024-Q3Increase in selling, general and administrative expenses, decrease in R&D expensesAnnual report
「Selling, general and administrative expenses increased by ¥1,496 million from the same period of the previous year, while R&D expenses decreased by ¥1,446 million」
For the first 3 quarters cumulatively, selling, general and administrative expenses increased by ¥1,496 million year on year, while R&D expenses decreased by ¥1,446 million. - FY2024-Q2Increase in selling, general and administrative expenses, decrease in R&D expensesAnnual report
「Meanwhile, selling, general and administrative expenses increased by ¥1,666 million from the same period of the previous year, while R&D expenses decreased by ¥656 million」
For the six months ended June 30, selling, general and administrative expenses increased by ¥1,666 million year on year, while R&D expenses decreased by ¥656 million. - FY2024-Q1Increase in selling, general and administrative expenses, decrease in R&D expensesAnnual report
「Selling, general and administrative expenses increased by ¥972 million from the same period of the previous year, while R&D expenses decreased by ¥273 million」
Selling, general and administrative expenses increased by ¥972 million year on year, while R&D expenses decreased by ¥273 million, representing a shift from the previous pattern of lower selling, general and administrative expenses and higher R&D expenses. - FY2023Decrease in selling, general and administrative expenses, increase in R&D expensesAnnual report
「Excluding R&D expenses, selling, general and administrative expenses decreased by ¥1,395 million from the previous fiscal year due to the decline in upfront payments for introduced products recorded in the previous year, cost-cutting measures and other factors, while R&D expenses increased by ¥2,005 million」
Excluding R&D expenses, selling, general and administrative expenses decreased by ¥1,395 million due to the decline in upfront payments for introduced products and cost-cutting measures, while R&D expenses increased by ¥2,005 million. - FY2023-Q3Decrease in selling, general and administrative expenses due to the decline in upfront payments from the previous yearAnnual report
「Selling, general and administrative expenses decreased from the same period of the previous year due to the decline in upfront payments for introduced products recorded in the previous year, while R&D expenses increased by ¥134 million」
Selling, general and administrative expenses decreased due to the decline in upfront payments for introduced products recorded in the previous year, while R&D expenses increased by ¥134 million. - FY2023-Q2Decrease in selling, general and administrative expenses due to the decline in upfront payments from the previous yearAnnual report
「Selling, general and administrative expenses decreased from the same period of the previous year due to the decline in upfront payments for introduced products recorded in the previous year, while R&D expenses increased by ¥134 million」
Selling, general and administrative expenses decreased due to the decline in upfront payments for introduced products recorded in the previous year, while R&D expenses increased by ¥134 million. - FY2022-Q3MitigatedAnnual report
「Despite the recognition of an upfront payment under an agreement related to the introduction of the cough treatment Lyfnua Tablets 45 mg (generic name: gefapixant citrate), selling, general and administrative expenses decreased from the same period of the previous year to ¥33,313 million due to cost-cutting measures and other factors, compared with ¥34,684 million in the same period of the previous year. R&D expenses were ¥6,571 million, compared with ¥7,603 million in the same period of the previous year.」
Although an upfront payment was incurred under the agreement for the introduction of Lyfnua, selling, general and administrative expenses and R&D expenses were below the level in the same period of the previous year due to cost-cutting measures and other factors. - FY2022-Q2MitigatedAnnual report
「Despite the recognition of an upfront payment under an agreement related to the introduction of a chronic cough treatment, selling, general and administrative expenses decreased from the same period of the previous year to ¥22,438 million due to cost-cutting measures and other factors, compared with ¥23,320 million in the same period of the previous year. R&D expenses were ¥4,364 million, compared with ¥5,200 million in the same period of the previous year.」
Although an upfront payment was incurred under the agreement for the chronic cough treatment, selling, general and administrative expenses and R&D expenses were below the level in the same period of the previous year due to cost-cutting measures and other factors. - FY2022-Q1WorsenedAnnual report
「Selling, general and administrative expenses, including R&D expenses, increased from the same period of the previous year due to the recognition of an upfront payment under an agreement related to the introduction of a chronic cough treatment.」
While cost-cutting measures continued, selling, general and administrative expenses exceeded the level in the same period of the previous year due to the upfront payment under the agreement to introduce a chronic cough treatment. - FY2021-Q3AdvancedAnnual report
「Due to cost-cutting measures in administrative divisions and the curtailment of medical representative activities in response to the spread of COVID-19, selling, general and administrative expenses decreased by ¥1,157 million from the same period of the previous year, while R&D expenses increased by ¥18 million」
Selling, general and administrative expenses were reduced by ¥1,157 million year on year due to cost-cutting measures in administrative divisions and the curtailment of medical representative activities. - FY2021-Q2AdvancedAnnual report
「Due to cost-cutting measures and the curtailment of medical representative activities at medical institutions in response to the spread of COVID-19, selling, general and administrative expenses decreased by ¥445 million from the same period of the previous year, while R&D expenses increased by ¥9 million」
Selling, general and administrative expenses were reduced by ¥445 million year on year due to cost-cutting measures and the curtailment of medical representative activities. - FY2021-Q1MitigatedAnnual report
「Due to cost-cutting measures and the curtailment of medical representative activities at medical institutions in response to the spread of COVID-19, selling, general and administrative expenses, including R&D expenses, decreased by ¥671 million from the same period of the previous year, including a ¥475 million decrease in R&D expenses」
Although selling, general and administrative expenses had increased in the previous full fiscal year, they decreased by ¥671 million year on year in the first quarter, including a ¥475 million decrease in R&D expenses. - FY2020WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥1,092 million from the previous fiscal year, including a ¥196 million increase in R&D expenses」
Selling, general and administrative expenses, which had previously been trending down, increased by ¥1,092 million year on year for the full year, while R&D expenses also increased by ¥196 million. - FY2020-Q3MitigatedAnnual report
「Selling, general and administrative expenses decreased by ¥215 million from the same period of the previous year, including a ¥150 million decrease in R&D expenses」
Selling, general and administrative expenses decreased by ¥215 million year on year, and R&D expenses also decreased by ¥150 million. - FY2020-Q2WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥15 million from the same period of the previous year, including a ¥160 million increase in R&D expenses」
Selling, general and administrative expenses, which had previously been declining, increased by ¥15 million year on year, while R&D expenses also increased by ¥160 million. - FY2020-Q1AdvancedAnnual report
「Selling, general and administrative expenses, including R&D expenses, decreased by ¥87 million from the same period of the previous year as the company pursued cost reductions」
Selling, general and administrative expenses were reduced by ¥87 million year on year, and cost-cutting efforts continue. - FY2019AdvancedAnnual report
「As a result of cost-cutting measures, selling, general and administrative expenses decreased by ¥4,316 million from the previous fiscal year, including a ¥3,452 million decrease in R&D expenses, thereby absorbing the decrease in gross profit」
Selling, general and administrative expenses were reduced by ¥4,316 million year on year, absorbing the decrease in gross profit. - FY2019-Q3AdvancedAnnual report
「As a result of cost-cutting measures, selling, general and administrative expenses decreased by ¥2,637 million from the same period of the previous year, including a ¥2,316 million decrease in R&D expenses」
The company continued to cut costs, reducing selling, general and administrative expenses by ¥2,637 million year on year, including a ¥2,316 million decrease in R&D expenses. - FY2019-Q2AdvancedAnnual report
「As a result of cost-cutting measures, selling, general and administrative expenses decreased by ¥2,437 million from the same period of the previous year, including a ¥2,148 million decrease in R&D expenses」
Selling, general and administrative expenses were reduced by ¥2,437 million year on year, including a ¥2,148 million decrease in R&D expenses. - FY2019-Q1AdvancedAnnual report
「Selling, general and administrative expenses, including R&D expenses, decreased by ¥126 million from the same period of the previous year as the company pursued cost reductions.」
The company continued to cut costs, reducing selling, general and administrative expenses by ¥126 million year on year. - FY2018AdvancedAnnual report
「As a result of cost-cutting measures, selling, general and administrative expenses decreased by ¥1,359 million from the previous fiscal year.」
Selling, general and administrative expenses were reduced by ¥1,359 million year on year while absorbing the increase in R&D expenses. - FY2018-Q3AdvancedAnnual report
「As a result of cost-cutting measures, selling, general and administrative expenses decreased by ¥2,557 million from the same period of the previous year, including a ¥802 million decrease in R&D expenses」
Selling, general and administrative expenses were reduced by ¥2,557 million year on year, including a ¥802 million decrease in R&D expenses. - FY2018-Q2AdvancedAnnual report
「The company pursued cost reductions in selling, general and administrative expenses, which decreased by ¥947 million from the same period of the previous year, including a ¥148 million decrease in R&D expenses.」
Selling, general and administrative expenses were reduced by ¥947 million year on year, including a ¥148 million decrease in R&D expenses. - FY2018-Q1First statedAnnual report
「We pursued cost reductions in selling, general and administrative expenses, which decreased by ¥852 million from the same period of the previous year, including a ¥537 million decrease in R&D expenses.」
SG&A expenses were reduced by ¥852 million year on year, including a ¥537 million reduction in R&D expenses.